Clinical Trials
Astrazeneca says asthma drug shows positive results in phase III trials
Results from pivotal Phase III trials presented at the ERS International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated...
Clinical Trials
CiToxLAB appoints Alan Bartlett as Senior Director, Global Laboratory Operations
CiToxLAB, a leading CRO in the field of non-clinical research, announces that Alan Bartlett has joined the company as Senior Director, Global Laboratory Operations, bringing with him 30 years’ experience in the development and implementation of laboratory support in...
Clinical Trials
Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations And $130M Series B
Denali Therapeutics Inc announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 million Series B equity financing. ...
Clinical Trials
CSM To Host A Live Webinar On Direct-To-Patient Shipping For Clinical Trials
CSM, a leading provider of clinical trial supply services, will conduct an upcoming webinar, "Discover How Direct-to-Patient Shipping is Changing Clinical Trials." This webinar, hosted by FierceMarkets, will explore how sponsor companies and CROs are adopting...
Clinical Trials
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
AstraZeneca and Eli Lilly and Company (Lilly) announced they have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial....
Clinical Trials
KalVista begins phase 1 study of KVD818 in hereditary angioedema
KalVista Pharmaceuticals announced the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818 in healthy volunteers. A KalVista discovery, KVD818 is a novel, potent,...
Clinical Trials
Alzheimer’s drug shows promise for patients in phase III trial
At the Alzheimer's Association International Conference 2016 (AAIC 2016), held in Toronto, Canada, researchers reveal how a drug called LMTX shows promise for halting the formation of tau tangles. Alzheimer's disease is estimated to affect 5.4...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
